Genetic engineering of the donor as an approach to clinical xenotransplantation.
Cozzi
E
E
Imutran Ltd (A Novartis Pharma AG Company), Cambridge, United Kingdom.
Soin
B
B
Holmes
B
B
White
D
D
D000818:Animals; D030801:Animals, Genetically Modified; D000910:Antibodies, Heterophile / Q000276:immunology; D015478:Antigens, Heterophile / Q000276:immunology; D005818:Genetic Engineering / Q000379:methods*; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D009844:Oligosaccharides / Q000276:immunology; D011323:Primates; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology / Q000379:methods*
D000910:Antibodies, Heterophile; D015478:Antigens, Heterophile; D009844:Oligosaccharides